QLT Inc. announced that QLT USA, Inc. has submitted a labelling supplement (sNDA) for Aczone to the US Food and Drug Administration (FDA) to request the removal of the glucose-6-phosphate dehydrogenase (G6PD) screening and blood monitoring requirements from its current label.
From: www.pharmabiz.com
QTL seeks label changes for Aczone from US FDA
Posted by Ruslan Abuzant at 10:14 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment